KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EBITDA (2016 - 2026)

Palvella Therapeutics has reported EBITDA over the past 10 years, most recently at -$9.8 million for Q3 2022.

  • Quarterly EBITDA rose 39.1% to -$9.8 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$34.8 million through Sep 2022, up 29.28% year-over-year, with the annual reading at -$41.6 million for FY2025, 138.86% down from the prior year.
  • EBITDA was -$9.8 million for Q3 2022 at Palvella Therapeutics, up from -$10.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $3.2 million in Q2 2018 and troughed at -$16.2 million in Q3 2021.
  • The 5-year median for EBITDA is -$9.4 million (2019), against an average of -$8.2 million.
  • Year-over-year, EBITDA surged 129.79% in 2018 and then tumbled 2305.67% in 2020.
  • A 5-year view of EBITDA shows it stood at -$11.6 million in 2018, then soared by 82.18% to -$2.1 million in 2019, then plummeted by 572.45% to -$13.9 million in 2020, then skyrocketed by 33.02% to -$9.3 million in 2021, then fell by 5.56% to -$9.8 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EBITDA are -$9.8 million (Q3 2022), -$10.7 million (Q2 2022), and -$5.0 million (Q1 2022).